ALDX vs. AVDL, ARDX, XERS, CRON, USNA, XNCR, KALV, RLAY, RGLS, and AMLX
Should you be buying Aldeyra Therapeutics stock or one of its competitors? The main competitors of Aldeyra Therapeutics include Avadel Pharmaceuticals (AVDL), Ardelyx (ARDX), Xeris Biopharma (XERS), Cronos Group (CRON), USANA Health Sciences (USNA), Xencor (XNCR), KalVista Pharmaceuticals (KALV), Relay Therapeutics (RLAY), Regulus Therapeutics (RGLS), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "med - drugs" industry.
Aldeyra Therapeutics vs. Its Competitors
Aldeyra Therapeutics (NASDAQ:ALDX) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.
Aldeyra Therapeutics has a net margin of 0.00% compared to Avadel Pharmaceuticals' net margin of -13.58%. Avadel Pharmaceuticals' return on equity of -36.07% beat Aldeyra Therapeutics' return on equity.
Aldeyra Therapeutics has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.
Avadel Pharmaceuticals has higher revenue and earnings than Aldeyra Therapeutics. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.
Aldeyra Therapeutics presently has a consensus target price of $9.50, suggesting a potential upside of 120.67%. Avadel Pharmaceuticals has a consensus target price of $18.17, suggesting a potential upside of 103.55%. Given Aldeyra Therapeutics' higher possible upside, analysts plainly believe Aldeyra Therapeutics is more favorable than Avadel Pharmaceuticals.
In the previous week, Avadel Pharmaceuticals had 9 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 10 mentions for Avadel Pharmaceuticals and 1 mentions for Aldeyra Therapeutics. Aldeyra Therapeutics' average media sentiment score of 1.85 beat Avadel Pharmaceuticals' score of -0.03 indicating that Aldeyra Therapeutics is being referred to more favorably in the media.
59.7% of Aldeyra Therapeutics shares are owned by institutional investors. Comparatively, 69.2% of Avadel Pharmaceuticals shares are owned by institutional investors. 9.6% of Aldeyra Therapeutics shares are owned by company insiders. Comparatively, 5.2% of Avadel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Avadel Pharmaceuticals beats Aldeyra Therapeutics on 9 of the 14 factors compared between the two stocks.
Get Aldeyra Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ALDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aldeyra Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ALDX) was last updated on 7/5/2025 by MarketBeat.com Staff
